Floatz logo

Escitalopram

Schizophrenia

Minerva NeurosciencesSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
65/ 100

Competitive context

141 Active assets in the Schizophrenia cohort.

View all 50

Same molecule, other indications

Escitalopram is also rated in:

bipolar I disorderActive
BBB
Indicative · Phase 4
77 / 100
View asset →
dysthymic disorderActive
BBB
Indicative · Phase 4
76 / 100
View asset →
depressive disorderActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →